Bharat Parenterals' Subsidiary, Innoxel Lifesciences, Out-Licenses Two Molecules to Leading Generic Pharma MNCs in the USA

Bharat Parenterals Limited's (BPL) subsidiary, Innoxel Lifesciences, has out-licensed two of its complex molecules to leading generic pharmaceutical multinational corporations (MNCs) based in the United States of America. The first molecule, a complex particulate injectable, has a market size of approximately USD 500 million as of 31st March 2024. Innoxel will receive total milestone payment of USD 4.5 million during the development and filing of the final Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (US FDA). Upon a successful launch, Innoxel will supply the formulation to its partner on a cost plus margin basis and will also be eligible to receive 20% of the profit sharing. The second molecule is for a 505 (b)(2)NDA opportunity in the oralliquid category, with a market opportunity estimated to be upwards of USD 400 million. Innoxel will receive total milestone payment of USD 1.95 million during the development and filling of the 505(b) (2) NDA with the USFDA. Upon successful launch, Innoxel will supply the formulation on cost plus margin basis and will also be eligible to receive 45% of the profit sharing.